- Home
- FCT vs TVRD Comparison
FCT vs TVRD Comparison
Compare FCT & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FCT
- TVRD
- Stock Information
- Founded
- FCT 2004
- TVRD 2017
- Country
- FCT United States
- TVRD United States
- Employees
- FCT N/A
- TVRD N/A
- Industry
- FCT Finance Companies
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- FCT Finance
- TVRD Health Care
- Exchange
- FCT Nasdaq
- TVRD Nasdaq
- Market Cap
- FCT 245.5M
- TVRD 246.5M
- IPO Year
- FCT N/A
- TVRD N/A
- Fundamental
- Price
- FCT $9.56
- TVRD $3.94
- Analyst Decision
- FCT
- TVRD Buy
- Analyst Count
- FCT 0
- TVRD 7
- Target Price
- FCT N/A
- TVRD $51.67
- AVG Volume (30 Days)
- FCT 106.8K
- TVRD 156.8K
- Earning Date
- FCT 01-01-0001
- TVRD 11-13-2025
- Dividend Yield
- FCT 11.29%
- TVRD N/A
- EPS Growth
- FCT N/A
- TVRD N/A
- EPS
- FCT N/A
- TVRD N/A
- Revenue
- FCT N/A
- TVRD N/A
- Revenue This Year
- FCT N/A
- TVRD N/A
- Revenue Next Year
- FCT N/A
- TVRD N/A
- P/E Ratio
- FCT N/A
- TVRD N/A
- Revenue Growth
- FCT N/A
- TVRD N/A
- 52 Week Low
- FCT $9.45
- TVRD $3.78
- 52 Week High
- FCT $10.42
- TVRD $43.65
- Technical
- Relative Strength Index (RSI)
- FCT 45.38
- TVRD 23.05
- Support Level
- FCT $9.42
- TVRD $3.78
- Resistance Level
- FCT $9.59
- TVRD $4.15
- Average True Range (ATR)
- FCT 0.09
- TVRD 0.29
- MACD
- FCT 0.01
- TVRD 0.87
- Stochastic Oscillator
- FCT 60.87
- TVRD 34.33
About FCT First Trust Senior Floating Rate Income Fund II of Beneficial Interest
First Trust Senior Floating Rate Income Fund II is a United States-based diversified, closed-end management investment company. Its investment objective is to seek a high level of current income. As a secondary objective, it attempts to preserve capital. The fund invests in a portfolio of senior secured floating-rate corporate loans (Senior Loans) of companies from different industries, such as Insurance, Software, Health Care Providers and Services, Professional Services, Health Care Technology, IT Services, and others.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.